Spinal Singularity Awarded Phase II SBIR Grant From NIH

SAN CLEMENTE, Calif., October 4, 2018 (Newswire.com) - Spinal Singularity announced that the company was awarded a Phase II SBIR grant from the National Institute of Health (NIH). The grant will provide approximately $1.5 Million in non-dilutive funding to continue clinical development of the Connected Catheter 2P (C2P).

Bill Colone, CEO of Spinal Singularity, said, “We are honored to receive this award from the NIH. This funding will finance a significant portion of the clinical study required to obtain regulatory approvals of the Connected Catheter 2P. We have partnered with world-class clinicians and research centers for this study and look forward to introducing innovative technology that improves the quality of life of our patients.”

We are honored to receive this award from the NIH. This funding will finance a significant portion of the clinical study required to obtain regulatory approvals of the Connected Catheter 2P. We have partnered with world-class clinicians and research centers for this study and look forward to introducing innovative technology that improves the quality of life of our patients.

Bill Colone, CEO of Spinal Singularity

Spinal Singularity has been developing the C2P, an innovative, smart catheter system designed for adult males with Chronic Urinary Retention and/or Neurogenic Lower Urinary Tract Dysfunction (NLUTD). Funds granted to Spinal Singularity will be utilized to conduct clinical studies of the C2P at the following clinical research sites.

Rancho Los Amigos National Rehabilitation Center Downey, CA - Drs. Evgeniy Kreydin and  David Ginsberg 

University of California, San Diego,  San Diego, CA - Drs. Yahir Santiago-Lastra and Michael Albo 

MedStar National Rehabilitation Hospital, Washington, D.C. - Dr. Suzanne Groah 

Derek Herrera, founder and CTO of Spinal Singularity, said, “We are so fortunate to have earned support from the NIH. I couldn’t be prouder of our team and the work they do on a daily basis to bring the C2P to market, where it may help millions of men who are chronic catheter users.”

Additional information about the clinical study can be accessed on ClinicalTrials.gov at https://clinicaltrials.gov/ct2/show/NCT03626324.

About Spinal Singularity Inc.

Spinal Singularity is a seed stage, venture-backed, medical device company developing products to improve the lives of patients with spinal injury. The company has developed the C2P, the first fully internal, smart catheter system for adult males with Urinary Retention. One C2P may replace up to 200 disposable intermittent catheters.  

For more information, please visit the company’s website at www.spinalsingularity.com.

The Connected Catheter is currently an INVESTIGATIONAL DEVICE ONLY and limited by federal (or United States) law to investigational use.

Bill Colone, CEO
105 Avenida de la Estrella #3
San Clemente, CA 92672
info@spinalsingularity.com
(949) 436-7974

Source: Spinal Singularity